The U.S. Food and Drug Administration’s Center for Veterinary Medicine (FDA-CVM) announced March 24, 2020, that it has approved Marboquin™, the first generic approval for marbofloxacin tablets, originally approved as Zeniquin®. Marboquin™ is in tablet form and is intended for the treatment of susceptible infections in dogs and cats.

Marbofloxacin, the active pharmaceutical ingredient in both Marboquin™ and Zeniquin®, is in the fluoroquinolone class of antibiotics. Fluoroquinolones are considered medically important antimicrobials in human medicine. Marboquin™, like Zeniquin®, is available only by prescription because a veterinarian’s expertise is necessary to determine whether treatment with marbofloxacin is appropriate.

The FDA granted the approval of Marboquin™ to Dechra Veterinary Products, LLC, of Overland Park, Kansas.

Click here to read the Freedom of Information Summary for Marboquin™.